SULFAMETHOXAZOLE AND TRIMETHOPRIM by Fosun Pharma is clinical pharmacology sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. First approved in 1982.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
Sulfamethoxazole and trimethoprim (SMX-TMP) is a fixed-dose combination antibiotic containing a sulfonamide and dihydrofolate reductase inhibitor that work synergistically to inhibit bacterial folate synthesis. It is indicated for urinary tract infections, Pneumocystis jirovecii pneumonia prophylaxis and treatment, and other bacterial infections. This combination is a classic broad-spectrum agent effective against gram-positive and gram-negative organisms.
LOE-approaching lifecycle indicates a mature, defended franchise with moderate competitive pressure (30/100) and likely smaller commercial teams focused on maintenance and generic transition planning.
CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized…
Worked on SULFAMETHOXAZOLE AND TRIMETHOPRIM at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on sulfamethoxazole-trimethoprim offers limited career growth opportunity given its LOE-approaching status, lack of clinical development, and zero linked job openings. Roles available are primarily defensive—focused on generic transition, cost containment, and patient access rather than commercial expansion or innovation.